A high-throughput screening strategy for detecting CRISPR-Cas9 induced mutations using next-generation sequencing

BMC Genomics

Andrew C Perkins²  Kevin R Gillinder¹  Graham W Magor¹  Charles C Bell¹ 

[1] Mater Research, Faculty of Medicine and Biomedical Science, The University of Queensland, Woolloongabba, Queensland, Australia;Department of Cancer Services, Princess Alexandra Hospital, Brisbane, Queensland, Australia

关键词: Indel;    Cas9;    CRISPR;    Screening strategy;    Next-generation sequencing;    Genome editing;    CRISPR-Cas9;   

Others  :  1091934
DOI  :  10.1186/1471-2164-15-1002

 received in 2014-09-05, accepted in 2014-11-06,  发布年份 2014

【 摘 要 】

Background

CRISPR-Cas9 is a revolutionary genome editing technique that allows for efficient and directed alterations of the eukaryotic genome. This relatively new technology has already been used in a large number of ‘loss of function’ experiments in cultured cells. Despite its simplicity and efficiency, screening for mutated clones remains time-consuming, laborious and/or expensive.

Results

Here we report a high-throughput screening strategy that allows parallel screening of up to 96 clones, using next-generation sequencing. As a proof of principle, we used CRISPR-Cas9 to disrupt the coding sequence of the homeobox gene, Evx1 in mouse embryonic stem cells. We screened 67 CRISPR-Cas9 transfected clones simultaneously by next-generation sequencing on the Ion Torrent PGM. We were able to identify both homozygous and heterozygous Evx1 mutants, as well as mixed clones, which must be identified to maintain the integrity of subsequent experiments.

Conclusions

Our CRISPR-Cas9 screening strategy could be widely applied to screen for CRISPR-Cas9 mutants in a variety of contexts including the generation of mutant cell lines for in vitro research, the generation of transgenic organisms and for assessing the veracity of CRISPR-Cas9 homology directed repair. This technique is cost and time-effective, provides information on clonal heterogeneity and is adaptable for use on various sequencing platforms.

【 授权许可】

   
2014 Bell et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Hsu P, Lander E, Zhang F: Development and applications of CRISPR-Cas9 for genome engineering. Cell 2014, 157:1262-1278.
• [2]Horvath P, Barrangou R: CRISPR/Cas, the immune system of bacteria and archaea. Science 2010, 327:167-170.
• [3]Sampson TR, Saroj SD, Llewellyn AC, Tzeng Y-L, Weiss DS: A CRISPR/Cas system mediates bacterial innate immune evasion and virulence. Nature 2013, 497:254-257.
• [4]Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA, Zhang F: Multiplex genome engineering using CRISPR/Cas systems. Science 2013, 339:819-823.
• [5]Sander JD, Joung JK: CRISPR-Cas systems for editing, regulating and targeting genomes. Nat Biotechnol 2014, 32:347-355.
• [6]Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F: Genome engineering using the CRISPR-Cas9 system. Nat Protoc 2013, 8:2281-2308.
• [7]Wang H, Yang H, Shivalila CS, Dawlaty MM, Cheng AW, Zhang F, Jaenisch R: One-step generation of mice carrying mutations in multiple genes by CRISPR/cas-mediated genome engineering. Cell 2013, 153:910-918.
• [8]Bikard D, Jiang W, Samai P, Hochschild A, Zhang F, Marraffini LA: Programmable repression and activation of bacterial gene expression using an engineered CRISPR-Cas system. Nucleic Acids Res 2013, 41:7429-7437.
• [9]Chen B, Gilbert LA, Cimini BA, Schnitzbauer J, Zhang W, Li G-W, Park J, Blackburn EH, Weissman JS, Qi LS, Huang B: Dynamic imaging of genomic loci in living human cells by an optimized CRISPR/Cas system. Cell 2013, 155:1479-1491.
• [10]Qi LS, Larson MH, Gilbert LA, Doudna JA, Weissman JS, Arkin AP, Lim WA: Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 2013, 152:1173-1183.
• [11]Yang H, Wang H, Shivalila CS, Cheng AW, Shi L, Jaenisch R: One-step generation of mice carrying reporter and conditional alleles by CRISPR/cas-mediated genome engineering. Cell 2013, 154:1370-1379.
• [12]Niu Y, Shen B, Cui Y, Chen Y, Wang J, Wang L, Kang Y, Zhao X, Si W, Li W, Xiang AP, Zhou J, Guo X, Bi Y, Si C, Hu B, Dong G, Wang H, Zhou Z, Li T, Tan T, Pu X, Wang F, Ji S, Zhou Q, Huang X, Ji W, Sha J: Generation of gene-modified cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos. Cell 2014, 156:836-843.
• [13]Yin H, Xue W, Chen S, Bogorad RL, Benedetti E, Grompe M, Koteliansky V, Sharp PA, Jacks T, Anderson DG: Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotechnol 2014, 32:551-553.
• [14]Yang H, Wang H, Jaenisch R: Generating genetically modified mice using CRISPR/Cas-mediated genome engineering. Nat Protoc 2014, 9:1956-1968.
• [15]Quail MA, Smith M, Coupland P, Otto TD, Harris SR, Connor TR, Bertoni A, Swerdlow HP, Gu Y: A tale of three next-generation sequencing platforms: comparison of Ion Torrent, Pacific Biosciences and Illumina MiSeq sequencers. BMC Genomics 2012, 13:341. BioMed Central Full Text
• [16]Hoffmann C, Minkah N, Leipzig J, Wang G, Arens MQ, Tebas P, Bushman FD: DNA bar coding and pyrosequencing to identify rare HIV drug resistance mutations. Nucleic Acids Res 2007, 35:e91.
• [17]Moran-Rivard L, Kagawa T, Saueressig H, Gross MK, Burrill J, Goulding M: Evx1 is a postmitotic determinant of v0 interneuron identity in the spinal cord. Neuron 2001, 29:385-399.
• [18]Bragg LM, Stone G, Butler MK, Hugenholtz P, Tyson GW: Shining a light on dark sequencing: characterising errors in ion torrent PGM data. PLoS Comput Biol 2013, 9:e1003031.
• [19]Loman NJ, Misra RV, Dallman TJ, Constantinidou C, Gharbia SE, Wain J, Pallen MJ: Performance comparison of benchtop high-throughput sequencing platforms. Nat Biotechnol 2012, 30:434-439.